Swiss Startup Life Biosystems Signs 10-Year ‘In Silico Discovery’ Deal with MD Anderson

Life Biosystems officials said the agreement is key to the company’s business strategy because it provides clinical data that will drive its discovery efforts, as well as access to research partners at the institute that can help validate the company’s discoveries.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories